Benzinga | May 19, 2021 08:10AM EDT

CNS Pharmaceuticals Commences Patient Enrollment In Potentially Pivotal Study Of Berubicin

CNS Pharmaceuticals, Inc.(NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced open enrollment for its potentially pivotal study evaluating the efficacy and safety of Berubicin in the treatment of recurrent GBM.